Astra Zeneca is a so-called toppval of the investment bank Bank of America Merrill Lynch during the current, first, quarter. It writes Reuters on Tuesday, pointing out that the stock market is overly pessimistic about Astra Zeneca.
The Swedish-british pharmaceutical company have an undervalued pipeline compared with peers.
the Analysis highlights the five drugs that have a potential of a total of 18 billion dollars in toppförsäljning waiting for phase 3 results in the coming 12-18 months, writes Reuters.
astrazeneca’s own assessment is that the group’s total sales in the year 2023 will amount to between 40-41 billion dollars.
Bank of America Merrill Lynch’s assessment of the five medicines toppförsäljning thus represents approximately 44-45% of the läkemedelsbolagets assessment of the total sales in the year 2023.
No comments:
Post a Comment